Acipimox reduces circulating levels of insulin and associated neutrophilic inflammation in metabolic syndrome

American Journal of Physiology - Endocrinology and Metabolism

Volumn 300, Issue 4, 2011, Pages 681-690

  Montecucco, Fabrizio ^a   Bertolotto, Maria ^b   Vuilleumier, Nicolas ^a   Franciosi, Ulisse ^b   Puddu, Alessandra ^b   Minetti, Silvia ^b   Delrio, Andrea ^b   Quercioli, Alessandra ^a,b   Bergamini, Ettore ^c   Ottonello, Luciano ^b   Pende, Aldo ^b   Lenglet, Sébastien ^a   Pelli, Graziano ^a   Mach, François ^a   Dallegri, Franco ^b   Viviani, Giorgio Luciano ^b  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF PISA   (Italy)

Author keywords

Atherosclerosis; Insulin resistance

Indexed keywords

ACIPIMOX; CHEMOKINE RECEPTOR CCR5; FATTY ACID; INSULIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MESSENGER RNA; RECOMBINANT HUMAN INSULIN;

ADULT; ARTICLE; ATHEROSCLEROSIS; CELL ISOLATION; CELL MIGRATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HEMATOLOGIC DISEASE; HUMAN; HUMAN CELL; IN VITRO STUDY; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; MONOCYTE; NEUTROPHIL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR; SINGLE DRUG DOSE; UPREGULATION;

ADMINISTRATION, ORAL; ADULT; ALGORITHMS; CELLS, CULTURED; DOWN-REGULATION; FEMALE; HUMANS; HYPOLIPIDEMIC AGENTS; INFLAMMATION; INSULIN; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NEUTROPHILS; PYRAZINES; TIME FACTORS;

EID: 79955164346     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00527.2010     Document Type: Article

References (35)

1. Azekoshi Y, Yasu T, Watanabe S, Tagawa T, Abe S, Yamakawa K, Uehara Y, Momomura S, Urata H, Ueda S. Free fatty acid causesleukocyte activation and resultant endothelial dysfunction through enhanced angiotensin II production in mononuclear and polymorphonuclear cells. Hypertension 56: 136-142, 2010.
2. Christie AW, McCormick DK, Emmison N, Kraemer FB, Alberti KG, Yeaman SJ. Mechanism of anti-lipolytic action of acipimox in isolated ratadipocytes. Diabetologia 39: 45-53, 1996.
3. Drechsler M, Megens RT, van Zandvoort M, Weber C, Soehnlein O. Hyperlipidemia-triggered neutrophilia promotes early atherosclerosis. Circulation 122: 1837-1845, 2010.
4. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 365: 1415-1428, 2005.
5. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults(Adult Treatment Panel III). JAMA 285: 2486-2497, 2001.
6. Fulop T, Tessier D, Carpentier A. The metabolic syndrome. Pathol Biol(Paris) 54: 375-386, 2006.
7. Holland WL, Knotts TA, Chavez JA, Wang LP, Hoehn KL, Summers SA. Lipid mediators of insulin resistance. Nutr Rev 65: S39-S46, 2007.
8. Ionita MG, van den Borne P, Catanzariti LM, Moll FL, de Vries JP, Pasterkamp G, Vink A, de Kleijn DP. High neutrophil numbers inhuman carotid atherosclerotic plaques are associated with characteristics of rupture-prone lesions. Arterioscler Thromb Vasc Biol 30: 1842-1848, 2010.
9. Kassi E, Dalamaga M, Faviou E, Hroussalas G, Kazanis K, Nounopoulos Ch, Dionyssiou-Asteriou A. Circulating oxidized LDL levels,current smoking and obesity in postmenopausal women. Atherosclerosis 205: 279-283, 2009.
10. Kendall DM, Sobel BE, Coulston AM, Peters Harmel AL, McLean BK, Peragallo-Dittko V, Buse JB, Fonseca VA, Hill JO, Nesto RW, Sunyer FX; Partners Against Insulin Resistance Advisory Panel. Theinsulin resistance syndrome and coronary artery disease. Coron Artery Dis 14: 335-348, 2003.
11. Lavezzari M, Milanesi G, Oggioni E, Pamparana F. Results of a phaseIV study carried out with acipimox in type II diabetic patients withconcomitant hyperlipoproteinaemia. J Int Med Res 17: 373-380, 1989.
12. Lindegaard B, Frøsig C, Petersen AM, Plomgaard P, Ditlevsen S, Mittendorfer B, Van Hall G, Wojtaszewski JF, Pedersen BK. Inhibition of lipolysis stimulates peripheral glucose uptake but has no effect onendogenous glucose production in HIV lipodystrophy. Diabetes 56: 2070-2077, 2007.
13. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and betacell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419, 1985.
14. Montecucco F, Bianchi G, Bertolotto M, Viviani G, Dallegri F, Ottonello L. Insulin primes human neutrophils for CCL3-induced migration:crucial role for JNK 1/2. Ann NY Acad Sci 1090: 399-407, 2006.
15. Montecucco F, Burger F, Pelli G, Poku NK, Berlier C, Steffens S, Mach F. Statins inhibit C-reactive protein-induced chemokine secretion,ICAM-1 upregulation and chemotaxis in adherent human monocytes. Rheumatology (Oxford) 48: 233-242, 2009.
16. Montecucco F, Lenglet S, Gayet-Ageron A, Bertolotto M, Pelli G, Palombo D, Pane B, Spinella G, Steffens S, Raffaghello L, Pistoia V, Ottonello L, Pende A, Dallegri F, Mach F. Systemic and intraplaque mediators of inflammation are increased in patients symptomatic for ischemic stroke. Stroke 41: 1394-1404, 2010.
17. Montecucco F, Mach F. Update on therapeutic strategies to increaseadiponectin function and secretion in metabolic syndrome. Diabetes ObesMetab 11: 445-454, 2009.
18. Montecucco F, Steffens S, Burger F, Da Costa A, Bianchi G, Bertolott OM, Mach F, Dallegri F, Ottonello L. Tumor necrosis factor-alpha (TNF-alpha) induces integrin CD11b/CD18 (Mac-1) up-regulation and migration to the CC chemokine CCL3 (MIP-1alpha) on human neutrophils through defined signalling pathways. Cell Signal 20: 557-568, 2008.
19. Montecucco F, Steffens S, Burger F, Pelli G, Monaco C, Mach F. C-reactive protein (CRP) induces chemokine secretion via CD11b/ICAM-1 interaction in human adherent monocytes. J Leukoc Biol 84: 1109-1119, 2008.
20. Montecucco F, Steffens S, Mach F. Insulin resistance: a proinflammatory state mediated by lipid-induced signaling dysfunction and involved in atherosclerotic plaque instability. Mediators Inflamm 2008: 767623, 2008.
21. Nakhjavani M, Khalilzadeh O, Khajeali L, Esteghamati A, Morteza A, Jamali A, Dadkhahipour S. Serum oxidized-LDL is associated with diabetes duration independent of maintaining optimized levels of LDLcholesterol. Lipids 45: 321-327, 2010.
22. Naruko T, Ueda M, Haze K, van der Wal AC, van der Loos CM, Itoh A, Komatsu R, Ikura Y, Ogami M, Shimada Y, Ehara S, Yoshiyama M, Takeuchi K, Yoshikawa J, Becker AE. Neutrophil infiltration ofculprit lesions in acute coronary syndromes. Circulation 106: 2894-2900,2002.
23. Ottonello L, Cutolo M, Frumento G, Arduino N, Bertolotto M, Mancini M, Sottofattori E, Dallegri F. Synovial fluid from patients with rheumatoid arthritis inhibits neutrophil apoptosis: role of adenosine andproinflammatory cytokines. Rheumatology (Oxford) 41: 1249-1260, 2002.
24. Salgin B, Marcovecchio ML, Humphreys SM, Hill N, Chassin LJ, Lunn DJ, Hovorka R, Dunger DB. Effects of prolonged fasting and sustained lipolysis on insulin secretion and insulin sensitivity in normalsubjects. Am J Physiol Endocrinol Metab 296: E454-E461, 2009.
25. Saloranta C, Groop L, Ekstrand A, Franssila-Kallunki A, Eriksson J, Taskinen MR. Different acute and chronic effects of acipimox treatment on glucose and lipid metabolism in patients with type 2 diabetes. Diabet Med 10: 950-957, 1993.
26. Saloranta C, Taskinen MR, Widen E, Härkönen M, Melander A, Groop L. Metabolic consequences of sustained suppression of free fatty acids by acipimox in patients with NIDDM. Diabetes 42: 1559-1566, 1993.
27. Santomauro AT, Boden G, Silva ME, Rocha DM, Santos RF, Ursich MJ, Strassmann PG, Wajchenberg BL. Overnight lowering of free fatty acids with Acipimox improves insulin resistance and glucose tolerance in obese diabetic and non diabetic subjects. Diabetes 48: 1836-1841, 1999.
28. Soehnlein O, Zernecke A, Eriksson EE, Rothfuchs AG, Pham CT, Herwald H, Bidzhekov K, Rottenberg ME, Weber C, Lindbom L. Neutrophil secretion products pave the way for inflammatory monocytes. Blood 112: 1461-1471, 2008.
29. Soehnlein O, Lindbom L. Phagocyte partnership during the onset and resolution of inflammation. Nat Rev Immunol 10: 427-439, 2010.
30. Soudijn W, van Wijngaarden I, Ijzerman AP. Nicotinic acid receptor subtypes and their ligands. Med Res Rev 27: 417-433, 2007.
31. Tabas I, Tall A, Accili D. The impact of macrophage insulin resistance on advanced atherosclerotic plaque progression. Circ Res 106: 58-67, 2010.
32. Taskinen MR, Nikkilä EA. Effects of acipimox on serum lipids, lipoproteins and lipolytic enzymes in hypertriglyceridemia. Atherosclerosis 69: 249-255, 1988.
33. Weber C, Zernecke A, Libby P. The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. Nat Rev Immunol 8: 802-815, 2008.
34. Wise A, Foord SM, Fraser NJ, Barnes AA, Elshourbagy N, Eilert M, Ignar DM, Murdock PR, Steplewski K, Green A, Brown AJ, Dowell SJ, Szekeres PG, Hassall DG, Marshall FH, Wilson S, Pike NB. Molecular identification of high and low affinity receptors for nicotinic acid. J Biol Chem 278: 9869-9874, 2003.
35. Zernecke A, Bot I, Djalali-Talab Y, Shagdarsuren E, Bidzhekov K, Meiler S, Krohn R, Schober A, Sperandio M, Soehnlein O, Bornemann J, Tacke F, Biessen EA, Weber C. Protective role of CXC receptor 4/CXC ligand 12 unveils the importance of neutrophils in atherosclerosis. Circ Res 102: 209-217, 2008.